

Alimta[®] (pemetrexed disodium) – First-time generic

- On May 27, 2022, [Dr. Reddy's](#), [Aurobindo](#), [Apotex](#), [Fresenius Kabi](#), [Zydus](#), and [Accord](#) launched AP-rated generic versions of Eli Lilly's [Alimta \(pemetrexed disodium\)](#) injection.
 - Additional AP-rated generics for Alimta were FDA-approved on May 25, 2022: [Hospira](#), [Jiangsu Hansoh](#), [Nang Kuang](#), [Qilu](#), and [Waverly](#). Launch dates for these generics are pending.
- Alimta is approved for the treatment of non-squamous non-small cell lung cancer and malignant pleural mesothelioma.
- Pemetrexed is also available as a brand intravenous solution ([Pemfexy[™]](#)) approved for the same indications as Alimta.
- According to IQVIA Health, Alimta had U.S. sales of approximately \$1.2 billion for the 12 months ending in March 2022.